Effect of Nabiximols On Goal Attainment Scale Scores in Patients With treatment-resistant Multiple Sclerosis Spasticity

References

• eMC . Sativex oromucosal spray. SmPC, (2020). www.medicines.org.uk/emc/product/602/smpc#gref
   Google Scholar
• Arroyo R , VilaC, ClissoldS. Retrospective observational study of the management of multiple sclerosis patients with resistant spasticity in Spain: the ‘5E’ study. Expert Rev. Pharmacoecon. Outcomes Res., 11(2), 205–213 (2011).
   PubMed Web of Science ®Google Scholar
• Arroyo R , MassanaM, VilaC. Correlation between spasticity and quality of life in patients with multiple sclerosis: the CANDLE study. Int. J. Neurosci., 123(12), 850–858 (2013).
   PubMed Web of Science ®Google Scholar
• Oreja-Guevara C , González-SeguraD, VilaC. Spasticity in multiple sclerosis: results of a patient survey. Int. J. Neurosci., 123(6), 400–408 (2013).
   PubMed Web of Science ®Google Scholar
• Svensson J , BorgS, NilssonP. Costs and quality of life in multiple sclerosis patients with spasticity. Acta Neurol. Scand., 129(1), 13–20 (2014).
   PubMed Web of Science ®Google Scholar
• Collin C , DaviesP, MutibokoIK, RatcliffeS. Sativex Spasticity in MS Study Group. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur. J. Neurol., 14(3), 290–296 (2007).
   PubMed Web of Science ®Google Scholar
• Collin C , EhlerE, WaberzinekGet al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol. Res., 32(5), 451–459 (2010).
   PubMed Web of Science ®Google Scholar
• Wade DT , CollinC, StottC, DuncombeP. Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult. Scler., 16(6), 707–714 (2010).
   PubMed Web of Science ®Google Scholar
• Novotna A , MaresJ, RatcliffeSet al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®)), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur. J. Neurol., 18(9), 1122–1131 (2011).
   PubMed Web of Science ®Google Scholar
• Markovà J , EssnerU, AkmazBet al. Sativex® as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial. Int. J. Neurosci., 129(2), 119–128 (2019).
   PubMed Web of Science ®Google Scholar
• Flachenecker P , HenzeT, ZettlUK. Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice--results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity. Eur. Neurol., 71(5–6), 271–279 (2014).
   PubMed Web of Science ®Google Scholar
• Koehler J , FenebergW, MeierM, PöllmannW. Clinical experience with THC:CBD oromucosal spray in patients with multiple sclerosis-related spasticity. Int. J. Neurosci., 124(9), 652–656 (2014).
   PubMed Web of Science ®Google Scholar
• Etges T , KaroliaK, GrintTet al. An observational postmarketing safety registry of patients in the UK, Germany, and Switzerland who have been prescribed Sativex® (THC:CBD, nabiximols) oromucosal spray. Ther. Clin. Risk Manag., 12, 1667–1675 (2016).
   PubMed Web of Science ®Google Scholar
• Patti F , MessinaS, SolaroCet al. Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. J. Neurol. Neurosurg. Psychiatry, 87(9), 944–951 (2016).
   PubMed Web of Science ®Google Scholar
• Notcutt WG . A questionnaire survey of patients and carers of patients prescribed Sativex as an unlicensed medicine. Prim. Health Care Res. Dev., 14(2), 192–199 (2013).
   PubMed Web of Science ®Google Scholar
• Arroyo R , VilaC, DechantKL. Impact of Sativex(®) on quality of life and activities of daily living in patients with multiple sclerosis spasticity. J. Comp. Eff. Res., 3(4), 435–444 (2014).
   PubMed Web of Science ®Google Scholar
• Kiresuk TJ , ShermanRE. Goal attainment scaling: a general method for evaluating comprehensive community mental health programs. Community Ment. Health J., 4(6), 443–453 (1968).
   PubMed Web of Science ®Google Scholar
• Khan F , PallantJF, Turner-StokesL. Use of goal attainment scaling in inpatient rehabilitation for persons with multiple sclerosis. Arch. Phys. Med. Rehabil., 89(4), 652–659 (2008).
   PubMed Web of Science ®Google Scholar
• Turner-Stokes L , WilliamsH, JohnsonJ. Goal attainment scaling: does it provide added value as a person-centred measure for evaluation of outcome in neurorehabilitation following acquired brain injury?J. Rehabil. Med., 41(7), 528–535 (2009).
   PubMed Web of Science ®Google Scholar
• Ashford S , Turner-StokesL. Goal attainment for spasticity management using botulinum toxin. Physiother. Res. Int., 11(1), 24–34 (2006).
   PubMedGoogle Scholar
• Ashford S , Turner-StokesL. Management of shoulder and proximal upper limb spasticity using botulinum toxin and concurrent therapy interventions: a preliminary analysis of goals and outcomes. Disabil. Rehabil., 31(3), 220–226 (2009).
   PubMed Web of Science ®Google Scholar
• Turner-Stokes L , FheodoroffK, JacintoJ, MaisonobeP, ZakineB. Upper limb international spasticity study: rationale and protocol for a large, international, multicentre prospective cohort study investigating management and goal attainment following treatment with botulinum toxin A in real-life clinical practice. BMJ Open, 3(3), e002230 (2013).
   PubMed Web of Science ®Google Scholar
• Turner-Stokes L , FheodoroffK, JacintoJ, MaisonobeP. Results from the Upper Limb International Spasticity Study-II (ULISII): a large, international, prospective cohort study investigating practice and goal attainment following treatment with botulinum toxin A in real-life clinical management. BMJ Open, 3(6), e002771 (2013).
   PubMed Web of Science ®Google Scholar
• Turner-Stokes L , AshfordS, JacintoJ, MaisonobeP, BalcaitieneJ, FheodoroffK. Impact of integrated upper limb spasticity management including botulinum toxin A on patient-centred goal attainment: rationale and protocol for an international prospective, longitudinal cohort study (ULIS-III). BMJ Open, 6(6), e011157 (2016).
   PubMed Web of Science ®Google Scholar
• Mahoney FI , BarthelDW. Functional evaluation: the Barthel Index. Md. State Med. J., 14, 61–65 (1965).
   PubMedGoogle Scholar
• Heesen C , HaaseR, MelzigSet al. Perceptions on the value of bodily functions in multiple sclerosis. Acta Neurol. Scand., 137(3), 356–362 (2018).
   PubMed Web of Science ®Google Scholar
• Turner-Stokes L . Goal attainment scaling (GAS) in rehabilitation: a practical guide. Clin. Rehabil., 23(4), 362–370 (2009).
   PubMed Web of Science ®Google Scholar
• Urach S , GaasterlandC, PoschMet al. Statistical analysis of Goal Attainment Scaling endpoints in randomised trials. Stat. Methods Med. Res., 28(6), 1893–1910 (2019).
   PubMed Web of Science ®Google Scholar
• Gehr S , KaiserT, KreutzR, LudwigWD, PaulF. Suggestions for improving the design of clinical trials in multiple sclerosis-results of a systematic analysis of completed phase III trials. EPMA J., 10(4), 425–436 (2019).
   PubMed Web of Science ®Google Scholar
• Polman CH , ReingoldSC, BanwellBet al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol., 69(2), 292–302 (2011).
   PubMed Web of Science ®Google Scholar
• Lublin FD , ReingoldSC, CohenJAet al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology, 83(3), 278–286 (2014).
   PubMed Web of Science ®Google Scholar
• Thompson AJ , BanwellBL, BarkhofFet al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol., 17(2), 162–173 (2018).
   PubMed Web of Science ®Google Scholar
• Farrar JT , TroxelAB, StottC, DuncombeP, JensenMP. Validity, reliability, and clinical importance of change in a 0–10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial. Clin. Ther., 30(5), 974–985 (2008).
   PubMed Web of Science ®Google Scholar
• Hobart JC , RiaziA, LampingDL, FitzpatrickR, ThompsonAJ. Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12). Neurology, 60(1), 31–36 (2003).
   PubMed Web of Science ®Google Scholar
• Guy W . National Institute of Mental Health (U.S.), Psychopharmacology Research Branch, Early Clinical Drug Evaluation Program. ECDEU Assessment Manual for Psychopharmacology.U.S. Dept. of. Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch. Division of Extramural Research Programs, MD, USA (1976).
   Google Scholar
• Veauthier C , HasselmannH, GoldSM, PaulF. The Berlin Treatment Algorithm: recommendations for tailored innovative therapeutic strategies for multiple sclerosis-related fatigue. EPMA J., 7(1), 25 (2016).
   PubMedGoogle Scholar
• Gaede G , TiedeM, LorenzIet al. Safety and preliminary efficacy of deep transcranial magnetic stimulation in MS-related fatigue. Neurol. Neuroimmunol. Neuroinflamm., 5(1), e423 (2017).
   PubMed Web of Science ®Google Scholar
• von Bismarck O , DankowskiT, AmbrosiusBet al. Treatment choices and neuropsychological symptoms of a large cohort of early MS. Neurol. Neuroimmunol. Neuroinflamm., 5(3), e446 (2018).
   PubMed Web of Science ®Google Scholar
• Mehta L , McNeillM, HobartJet al. Identifying an important change estimate for the Multiple Sclerosis Walking Scale-12 (MSWS-12v1) for interpreting clinical trial results. Mult. Scler. J. Exp. Transl. Clin., 1, 2055217315596993 (2015).
   Google Scholar
• Motl RW , PutzkiN, PiluttiLA, CadavidD. Longitudinal changes in self-reported walking ability in multiple sclerosis. PLoS ONE, 10(5), e0125002 (2015).
   PubMed Web of Science ®Google Scholar